A COVID-19 vaccine candidate developed by Sinopharm could be ready for public use by the end of this year, according to state media, ahead of a previous expectation it may become available in 2021, as reported in This is Money.
Sinopharm Chairman Liu Jingzhen said the company anticipates completing late-stage clinical testing within about three months.
Sinopharm's China National Biotec Group unit, which is responsible for two coronavirus vaccine projects, said last month that the vaccine may not be ready until at least 2021 as a lack of new infections in China made it difficult to find people to test it on.
Sinopharm's experimental vaccine has entered a Phase III trial involving around 15,000 participants and two vaccine strains in the United Arab Emirates.
To read more NewsPoints articles, click here.